EDAP TMS Treats First Patient with HIFU in Pancreatic Cancer Trial
• EDAP TMS SA has initiated a Phase I/II trial (PULS) using High Intensity Focused Ultrasound (HIFU) for pancreatic tumor treatment.
• The first patient with locally advanced pancreatic cancer was treated successfully in the PULS trial, showing tolerance to the HIFU intervention.
• The PULS trial aims to evaluate both the tolerance and preliminary efficacy of intraoperative HIFU for unresectable pancreatic tumors.
• This milestone reflects EDAP's commitment to innovative therapies for areas of significant unmet medical need, like pancreatic cancer.
Siremadlin Plus Ribociclib Shows Promise in MDM2/CDK4-Amplified Liposarcoma
• The combination of siremadlin and ribociclib demonstrates encouraging efficacy and a manageable safety profile in patients with advanced MDM2/CDK4-amplified liposarcoma.
• In a subset of liposarcoma patients, the combination therapy resulted in a median overall survival of 23 months, significantly longer than historical controls.
• The MEGAMOST trial suggests that targeting both MDM2 and CDK4/6 pathways may be a beneficial therapeutic approach in liposarcomas with specific genetic profiles.
• The study highlights the potential of molecularly driven treatment strategies to improve outcomes in advanced solid tumors.
© Copyright 2025. All Rights Reserved by MedPath